An Observational Study of Inflammatory Bowel Disease (IBD) Patients With Non-alcoholic Fatty Liver Disease (NAFLD)

Launched by SHANGHAI EAST HOSPITAL · Apr 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the relationship between Inflammatory Bowel Disease (IBD), which includes conditions like ulcerative colitis and Crohn's disease, and non-alcoholic fatty liver disease (NAFLD). Researchers want to understand how having NAFLD affects the symptoms and treatment outcomes of IBD in patients. They are collecting information from a group of IBD patients to see if there are differences between those who have NAFLD and those who do not, and how NAFLD might influence the effectiveness of IBD treatments.

To participate in this study, you need to be at least 18 years old and diagnosed with IBD according to specific guidelines. You should also be able to attend follow-up visits and give your consent to participate. The study aims to gather important data that can help improve the understanding and treatment of IBD in China. Participants can expect to provide blood samples and answer questions about their health, which will contribute to valuable research on these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subjects aged over 18 years (including borderline values), of either sex.
• • 2. Subjects consistented with the Chinese consensus on the diagnosis and treatment of IBD;
• • 3. Subjects able to cooperate with follow-up, participate in this study and sign the informed consent.
• Exclusion Criteria:
• • 1. Subjects with incomplete clinical data;
• • 2. Subjects can not to cooperate with follow-up, and refuse to sign the informed consent;
• • 3. Subjects can not to cooperate with the completion of relevant examinations; 4 Pregnant women;
• • 5.Subjects with severe heart, lung, kidney and other organ diseases or cancer, and expected survival time less than 6 months.